MSD is spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company (“NewCo”)

Kenneth C. Frazier, Chairman and CEO of MSD & Co., Inc.

  • Served as the chairman and CEO of MSD since 2011
  • Under Frazier’s leadership, MSD is delivering innovative lifesaving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders. Frazier has substantially increased MSD’s investment in research while refocusing the organization on the launch and growth of key products that provide benefit to society
  • Previously served as president of MSD; executive vice president and president, Global Human Health; and executive vice president and general counsel at MSD
  • Prior to joining MSD, Frazier was a partner with the Philadelphia, PA, law firm Drinker Biddle & Reath
  • Sits on boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation, and Cornerstone Christian Academy in Philadelphia
  • Member of the American Academy of Arts and Sciences, American Philosophical Society, Business Council, Council of the American Law Institute, and American Bar Association

Read Full Bio

Kevin Ali, Appointed CEO of NewCo

  • Currently serves as senior vice president, leading MSD’s enterprise portfolio strategy including responsibility for strategic review of MSD’s Human Health portfolio, and reports directly to Chairman and CEO Kenneth C. Frazier
  • Has 3 decades of pharmaceutical and commercial experience with extensive knowledge of MSD’s portfolio and operations, as well as the pharmaceutical industry and customer landscape
  • Previously president of MSD, where he established a central organizational structure and led MSD’s operations in all countries outside the US, a significant driver of the company’s growth and financial results
  • In his prior role as president of emerging markets, Ali achieved sustained growth performance in many markets, and introduced several important commercial partnerships and agreements critical to market expansion
  • Prior senior leadership roles include senior vice president and general manager of the Bone, Respiratory, Immunology, and Dermatology franchise; senior vice president and managing director of MSD Germany; and managing director of MSD Turkey, among others

Read Full Bio

Carrie Cox, Appointed Chairman of NewCo

  • Former chairman and CEO of Humacyte from 2010 until June 2018, and executive chairman into 2019
  • Previously executive vice president and president of Global Pharmaceuticals at Schering-Plough from 2003 until its merger with MSD in November 2009. Under her leadership, the business delivered substantial revenue growth
  • Prior roles included president of Global Prescription Business at Pharmacia Corporation, senior vice president of global business management at Pharmacia & Upjohn (Pharmacia’s predecessor), and vice president of Women’s Healthcare at Wyeth-Ayerst
  • Currently on the Boards of Directors of Texas Instruments, Cardinal Health, and Selecta Biosciences
  • Named 6 times to FORTUNE Magazine’s list of the “50 Most Powerful Women in Business” and featured in the Harvard Business Review and in The New York Times bestseller The Profit Zone

Read Full Bio

Matthew Walsh, Appointed CFO of NewCo

  • Joins NewCo from Allergan, where he served as Executive Vice President and Chief Financial Officer since February 2018
  • Seasoned finance executive with over 15 years of public company CFO experience. Brings a healthcare background from his prior role with Allergan and from Catalent, where he served as EVP, CFO for 10 years
  • Before Catalent, served as President, CFO and Acting CEO at Escala Group, Inc.
  • Previously held a variety of finance leadership roles at GenTek, Inc., including Vice President-Finance & Chief Financial Officer, Vice President & Treasurer and Group Controller

Read Full Bio

Rachel Stahler, Appointed CIO of NewCo

  • Joins NewCo from Allergan where she recently served as CIO
  • Brings expertise in a broad range of information technology disciplines combined with a passion for bringing innovative new treatments to patients in need
  • Prior to Allergan, held CIO positions in multiple global healthcare organizations including Syneos Health/Inventiv Health and Optimer Pharmaceuticals
  • Spent eight years at Pfizer, Inc., where she held senior level roles in its pharmaceutical and diversified businesses, including technology lead for a Global Center of Excellence for a significant business unit and global technology leadership positions for sales, marketing, market access, strategy and multiple therapeutic areas
  • Previously worked as a consultant at PriceWaterhouseCoopers

Read Full Bio

Deborah H. Telman, Appointed Senior Vice President, General Counsel of NewCo

  • Joins NewCo from Sorrento Therapeutics, where she served as Senior Vice President, General Counsel and Corporate Secretary leading the legal, compliance, human resource and quality functions
  • Spent more than 20 years in senior executive roles at several global companies including Abbott, Johnson Controls and Boeing
  • Before Sorrento Therapeutics, served as General Counsel at Johnson Controls for four years

Read Full Bio